The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo

Non-responders to checkpoint inhibitors generally have low tumor T cell infiltration and could benefit from immunotherapy that activates dendritic cells, with priming of tumor-reactive T cells as a result. Such therapies may be augmented by providing tumor antigen in the form of cancer vaccines. Our...

Descripción completa

Detalles Bibliográficos
Autores principales: Deronic, Adnan, Nilsson, Anneli, Thagesson, Mia, Werchau, Doreen, Enell Smith, Karin, Ellmark, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571159/
https://www.ncbi.nlm.nih.gov/pubmed/33948686
http://dx.doi.org/10.1007/s00262-021-02932-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571159/
https://www.ncbi.nlm.nih.gov/pubmed/33948686
http://dx.doi.org/10.1007/s00262-021-02932-5

Ejemplares similares